comparemela.com

Latest Breaking News On - Shishir vayttaden - Page 1 : comparemela.com

In conversation with Cyril Amarchand Mangaldas Partner and author of Kill the Lawyers, Shishir Vayttaden

Whacky Tales around the Diabolical Ways of Big Law Firms

Moneylife does not usually review books of fiction, so why is Kill the Lawyers: Small Tales of Big Law an exception? Not because of the twists in its fascinating tales that make you laugh or the sharp prose, but because it is a must-read for India s newly minted market mavens who are usually clueless about the puppeteering of corporate giants with big law muscle.

Fiction: A lawyer has fun with the law while helping clients through dire straits

Cyril Amarchand Mangaldas advises on L&T Technology Services acquisition of Smart World and Communication Business of L&T on slump sale basis

Mumbai (Maharashtra)/New Delhi [India], January 19 (ANI/BusinessWire India): Cyril Amarchand Mangaldas advised Larsen and Toubro Limited (L&T), in relation to sale of its 'Smart World and Communications Business' (SW&C Business) to its listed subsidiary L&T Technology Services Limited (LTTS), for an aggregate amount of INR 800 crore. The Transaction seeks to leverage LTTS's global footprint and achieve a global market reach for the SW&C Business. The General Corporate Practice of Cyril Amarchand Mangaldas acted as the legal counsel for L&T Group in the transaction. The transaction team was led by Shishir Vayttaden, Partner; and Aditi Singhvi, Partner; with the support of Riya Sharma, Associate. The diligence was conducted by Aditi Singhvi, Partner; with support from Shreejoyee Bhattacharya, Associate; Rajat Sinha, Associate; Kabeer Jay, Associate; Tawishi Beria, Associate; and Pritha Taraphder, Associate. The Employement team was lead Bishen Jeswant, Par

Cyril Amarchand Mangaldas advises sellers on Rs 9,500 Crore acquisition by Advent

Mumbai (Maharashtra)/ New Delhi [India], January 3 (ANI/BusinessWire India): Cyril Amarchand Mangaldas advised the promoters of Suven Pharmaceuticals Limited (Suven Pharmaceuticals) in relation to the acquisition of Suven Pharmaceuticals by global private equity firm Advent, for an aggregate amount of Rs 9,500 crore (approx.) through a share purchase agreement for c

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.